Mick is an optometrist and residency director at the San Francisco VA Medical Center, a clinical professor at UC Berkeley Herbert Wertheim School of Optometry and Vision Science and holds a volunteer faculty appointment at the UC San Francisco department of ophthalmology
Long-Acting Insulin (e.g., detemir, glargine U-100) Provides a steady release for 2024 hours with no pronounced peak, supporting basal blood sugar control
During your consultation, we look at weight trajectory, prior programs attempted, eating patterns, metabolic risk, and realistic timelines
It is used as a weight loss medication, available only by prescription and is a weekly injection under the skin (subcutaneous injection)
we're committed to empowering researchers with the most accurate, detailed, and human-centric insights possible
Frequently Asked Questions How can GLP1 medications help manage obesity in people with type 1 diabetes